Iovanace Biotherapeutics (IOVA) Upgraded to Buy at Stifel, FDA Hire Likely to Help Resolve Assay Potency Issue
Tweet Send to a Friend
Stifel analyst Benjamin Burnett upgraded Iovanace Biotherapeutics (NASDAQ: IOVA) from Buy to Hold with a price target of $25.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
